Angiogenesis, or the formation of new capillary blood vessels, occurs primarily during
human development and reproduction; however, aberrant regulation of angiogenesis is also …

The treatment of advanced non-small cell lung cancer (NSCLC) may be changing, but the
cisplatin-based doublet remains the foundation of treatment for the majority of patients with …

Background Angiogenesis is a validated clinical target in advanced epithelial ovarian
cancer. Cediranib is an oral antiangiogenic vascular endothelial growth factor receptor 1–3 …

Over the past few years, there have been considerable advances in the treatments available
to patients with metastatic or locally advanced NSCLC, particularly those who have …

Background Previous findings showed that cediranib-olaparib increased PFS in women with
recurrent platinum-sensitive ovarian cancer compared to olaparib alone. Methods …

Angiogenesis is a complex biological process that plays a relevant role in sustaining the
microenvironment, growth, and metastatic potential of several tumors, including non-small …

In many cancers, including non-small cell lung cancer (NSCLC), tumor angiogenesis
pathways have been identified as important therapeutic targets. Angiogenesis is essential in …

Background Patients treated with standard chemotherapy for metastatic or relapsed cervical
cancer respond poorly to conventional chemotherapy (response achieved in 20–30% of …

Lung cancer remains the single deadliest cancer both in the US and worldwide. The great
majority of squamous cell carcinoma (SCC) is attributed to cigarette smoking, which …

Purvalanol A is a highly selective inhibitor of Cdc2 [also known as cyclin-dependent kinase
1 (CDK1)]. Taxol is an anti-tumor chemotherapeutic drug which is widely used clinically. In …